Mounjaro's dose ladder, 2.5, 5, 7.5, 10, 12.5 and 15 milligrams, generates more anxiety than almost any other part of treatment. People worry they are climbing too slowly, envy strangers on higher doses, and wonder whether staying put means settling for less. The reality is calmer: the ladder is a framework for individualising treatment, not a league table, and the decision to climb is a clinical judgement with well-understood inputs. This article explains those inputs, so your dose reviews feel like informed conversations rather than verdicts.
How the ladder is designed to work
Everyone starts at 2.5 mg for four weeks. That dose is explicitly a tolerability introduction, letting the digestive system adapt to slower stomach emptying before the medicine reaches working strength. From week five the standard move is to 5 mg, and thereafter increases of 2.5 mg can follow at minimum four-week intervals, if needed and if tolerated. Those two conditions carry the whole system. If needed means the current dose is not producing adequate appetite and weight response; if tolerated means side effects at the current dose have settled to something comfortably manageable. The four-week minimum exists because levels take about that long to reach steady state after each change, so judging a dose sooner is judging an incomplete picture. Nothing in the design obliges anyone to reach 15 mg; the licence explicitly anticipates people maintaining at middle doses.
The case for moving up
The signal that a dose increase is worth discussing is fading or insufficient effect once the dose has had its fair run: appetite suppression that was strong in the first weeks loosening noticeably, food noise returning, portions creeping back up, and the weight trend flattening for a month or more despite honest habits. Trial data supports the logic of headroom, with average weight loss rising from roughly 15% at 5 mg to around 21% at 15 mg in SURMOUNT-1, so there is genuinely more effect available upstairs for those who need it and handle it. The distinction that matters is between a dose that has stopped working hard enough and a plateau caused by something else, hidden calories, a lighter body needing fewer calories, ordinary scale noise. That is why prescribers ask about appetite specifically: a flat month with strong appetite suppression points away from the dose, while a flat month with returning hunger points towards it.
The case for staying put
There are three good reasons not to climb. The first is that things are working: steady weight loss, manageable appetite, ordinary life continuing. A working dose does not need improving, and restraint preserves headroom for later, when plateaus arrive naturally. The second is unsettled side effects: escalating while nausea, reflux or bowel symptoms are still rough almost always amplifies them, whereas another month of settling first usually makes the eventual step smoother. The third is approaching your goal: near target weight, the job shifts from losing to maintaining, and pushing doses higher adds little except side-effect risk. Staying at a dose long term is not failure; in the trials, plenty of successful outcomes ran through the middle rungs. There is also a legitimate downward direction, stepping back when side effects outweigh benefit, which prescribers use routinely.
Why the increases sometimes feel compulsory
A common confusion deserves clearing up: many people believe the dose must keep rising on schedule, because the early months make it feel that way. The 2.5 mg to 5 mg move is near-universal since the starting dose is sub-therapeutic for most, and momentum from that first step creates the impression of a conveyor. It is not one. After 5 mg, every further step is optional and conditional, and prescribing guidance frames it exactly that way. The body also adapts around each increase, side effects flare for days to a couple of weeks then settle, appetite suppression deepens then stabilises, so part of the skill is distinguishing the temporary turbulence of a recent step from a genuine mismatch. Keeping a simple weekly log of appetite, side effects and weight turns those impressions into evidence your prescriber can actually use, and it takes two minutes a week to maintain.
What never to do
Two improvisations cause genuine harm. Do not self-escalate, whether by dialling a higher dose than prescribed, shortening the interval, or sourcing extra pens outside your prescription; the four-week minimums and tolerability checks are the safety architecture, and skipping them trades a few weeks of impatience for weeks of avoidable sickness or worse. And do not stretch or split doses to economise without your prescriber's involvement, because irregular dosing delivers unpredictable levels: enough side effects to be unpleasant, not enough sustained effect to work. If cost or supply is the pressure, say so plainly at review; legitimate options, from dose strategy to switching treatments, exist for exactly those conversations. The pen in your fridge should always match the plan in your notes.
The dose ladder, used properly, is a series of deliberate decisions: four weeks minimum per rung, climb only when effect is insufficient and side effects are settled, stay wherever the balance is right, and never improvise alone. Bring data to reviews, ask the explicit question, is there a reason to move, and trust that more milligrams are a tool rather than a trophy. For the surrounding picture, see our guides to how long Mounjaro takes to work, its side effects, and why weight sometimes stalls despite the medicine.